Trial reportPsychopharmacology2011
Peripheral biomarkers of cognitive response to dopamine receptor agonist treatment.
Trial report in Psychopharmacology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Dopamine agonists for the treatment of cocaine dependence.The Cochrane database of systematic reviews · 2015Pooled it
- Impaired Learning From Negative Feedback in Stimulant Use Disorder: Dopaminergic Modulation.The international journal of neuropsychopharmacology · 2021Trial
- Beta-Blocker Propranolol Modulates Decision Urgency During Sequential Information Gathering.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2018Trial
- Dopamine effects on evidence gathering and integration.Journal of psychiatry & neuroscience : JPN · 2015Trial
- Safety of atomoxetine in combination with intravenous cocaine in cocaine-experienced participants.Journal of addiction medicine · 2012Trial
- Indecision and recency-weighted evidence integration in non-clinical and clinical settings.Nature human behaviour · 2026Article
- Monocyte-Derived Macrophages Expressing Dopamine D2-Subtype Receptors Drive Alcohol Effects on Mesolimbic Neurons and Microglia.Biomedicines · 2025Article
- Cognitive Dysfunction in the Addictions (CDiA): protocol for a neuron-to-neighbourhood collaborative research program.Frontiers in psychiatry · 2025Article
- Substance withdrawal during psychotherapy incorporating equines: A preliminary investigation of the role of neurotransmitters during treatment.Journal of equine rehabilitation · 2025Article
- The mediating role of frequent mental distress in the relationship between adverse childhood experiences and cognitive disability in emerging adults.Scientific reports · 2024Article
- Multimodal analysis demonstrating the shaping of functional gradients in the marmoset brain.Nature communications · 2022Article
- The peripheral dopamine 2 receptor antagonist domperidone attenuates ethanol enhancement of dopamine levels in the nucleus accumbens.Alcoholism, clinical and experimental research · 2022Article
- Biomarkers of Major Depressive Disorder: Knowing is Half the Battle.Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology · 2021Review
- Multimodal investigation of dopamine DNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Article
- Peripheral Dopamine in Restless Legs Syndrome.Frontiers in neurology · 2018Article
- Increased decision thresholds enhance information gathering performance in juvenile Obsessive-Compulsive Disorder (OCD).PLoS computational biology · 2017Article
- Protein biomarkers of mood disorders.International journal of immunopathology and pharmacology · 2017Review
- Peripheral Serotonin 1B Receptor Transcription Predicts the Effect of Acute Tryptophan Depletion on Risky Decision-Making.The international journal of neuropsychopharmacology · 2017Article
- Peripheral Immune Cell Populations Associated with Cognitive Deficits and Negative Symptoms of Treatment-Resistant Schizophrenia.PloS one · 2016Article
- The dopamine D3 receptor gene and posttraumatic stress disorder.Journal of traumatic stress · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 4 institutions in 2 countries.
Funding
Abstract
rationaleUsing biological markers to objectively measure addiction severity or to identify individuals who might benefit most from pro-cognitive treatment could potentially revolutionize neuropsychopharmacology. We investigated the use of dopamine receptor mRNA levels in circulating blood cells as predictors of cognitive response following dopamine agonist treatment, and as biomarkers of the severity of stimulant drug dependence. METHODOLOGY: We employed a double-blind, placebo-controlled cross-over design, administering a single dose of the selective dopamine D(2/3) receptor agonist pramipexole (0.5 mg) to increase dopamine transmission in one session and a placebo treatment in another session in 36 volunteers. Half the volunteers had a formal diagnosis of stimulant dependence, while half had no psychiatric history. Participants performed neurocognitive tests from the CANTAB battery on both occasions, and stimulant-dependent individuals rated drug craving using visual analog scales. Whole-blood mRNA levels were measured for three dopamine-related genes: DRD3 and DRD4 (dopamine receptors), and catechol-O-methyltransferase (COMT; a dopamine catabolic enzyme).
resultsStimulant users performed worse than healthy volunteers on the cognitive tests. The variation in peripheral dopamine D(3) receptor mRNA expression explained over one quarter of the variation in response to pramipexole on the spatial working memory test across all participants. The severity of stimulant dependence was also significantly associated with peripheral COMT mRNA expression in stimulant users.
conclusionsPeripheral expression of dopamine-related genes may be useful as a biomarker of cognitive response to dopamine agonist drugs and of severity of addiction to dopamine-releasing stimulant drugs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.